Emerging Opportunities in Dato-DXd Market: Global Insights 2026
Dato-DXd, also known commercially as DATROWAY or datopotamab deruxtecan, is a TROP2-targeted antibody-drug conjugate (ADC) developed using Daiichi Sankyo’s proprietary DXd ADC technology. As one of the six DXd ADCs in Daiichi Sankyo’s oncology pipeline and a key program in AstraZeneca’s ADC platform, Dato-DXd represents a major advancement in precision oncology. The therapy combines a humanized anti-TROP2 IgG1 monoclonal antibody with topoisomerase I inhibitor payloads through tetrapeptide-based cleavable linkers, developed in collaboration with Sapporo Medical University.
At a dose of 6 mg/kg, DATROWAY has been approved in more than 35 countries for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously received endocrine-based therapy and chemotherapy. These approvals are supported by the pivotal TROPION-Breast01 trial. Additionally, in Russia and the U.S., Dato-DXd is approved for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) after prior EGFR-targeted therapy and platinum-based chemotherapy, as demonstrated in the TROPION-Lung05 and TROPION-Lung01 trials. Ongoing confirmatory studies may be required to maintain U.S. approval for NSCLC.
Dato-DXd is also being evaluated in Phase II/III trials for Urothelial Cancer (NCT07129993) and Phase II studies for Solid Tumors and Gastric Cancer (NCT05489211). This diverse clinical pipeline emphasizes the potential of Dato-DXd marketed drugs overview to expand across multiple oncology indications, creating opportunities for global adoption.
In December 2025, the European Medicines Agency (EMA) validated a Type II Variation marketing authorization for DATROWAY as a monotherapy for first-line treatment of adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitors. In October 2025, results from the TROPION-Breast02 Phase III trial revealed that DATROWAY significantly improved overall survival (OS) and progression-free survival (PFS) compared to investigator’s choice chemotherapy in locally recurrent inoperable or metastatic TNBC patients where immunotherapy was not an option.
The Dato-DXd market assessment is constructed through a combination of primary and secondary research, proprietary databases, and expertise from DelveInsight’s industry specialists. Secondary sources include regulatory authority platforms, trade journals, white papers, news portals, and publicly available datasets. This comprehensive approach ensures robust and actionable insights into Dato-DXd market trends, adoption rates, and competitive dynamics.
DelveInsight provides an in-depth Dato-DXd insight, including Dato-DXd sales forecast and projections for approved indications such as HER2-negative breast cancer, NSCLC, and TNBC, as well as potential markets in Urothelial Cancer, Solid Tumors, and Gastric Cancer. The analysis spans major geographies including the U.S., EU4 (Germany, France, Italy, Spain), the U.K., and Japan. Detailed evaluations cover Dato-DXd cost analysis, Dato-DXd pricing, Dato-DXd pipeline, Dato-DXd API manufacturers, and market dynamics to inform stakeholders on strategic positioning. Forecasting up to 2034 highlights the Dato-DXd market size and forecast and anticipated Dato-DXd CAGR growth, offering critical guidance for commercial strategy and adoption trends.
The Dato-DXd segment exemplifies innovation in targeted oncology therapeutics. With a growing clinical pipeline, expanding regulatory approvals, and rising demand for precision therapies, Dato-DXd marketed drugs are set to make a significant clinical and commercial impact worldwide. Strategic insights from DelveInsight equip pharmaceutical stakeholders to optimize market entry, production planning, and patient access in key cancer indications.
Tropical Spastic Paraparesis Market | Vulvar Cancer Market | Diabetes Insipidus Market | Surgical Energy Instruments Market | Plasmodium Vivax Malaria Market | Facial Lines Market | Pigment Epithelial Detachment Market | Peripheral Vascular Devices Market | Antibody Drug Conjugate Market | Bowel Obstruction Market | Liquid Biopsy for Cancer Diagnostics Market | Soft Tissue Sarcoma with Lung Metastasis Market | Urinary Incontinence Devices Market | Advanced Liver Cancer Market | Atopic Dermatitis Market | Bone Growth Stimulator Market | Endoscopic Ultrasound Market | Herpes Zoster Market | Immune Thrombocytopenia Market | Keloid Market | Monoclonal Gammopathy of Undetermined Significance Market | Myopia Progression Market | Neurodermatitis Market | Novel Drug Delivery Devices Market | Paranasal Sinus Cancer Market | Peanut Allergy Market Report | Penile Cancer Market | Postpartum Depression Market | Radiation Dermatitis Market | Septic Shock Market | Transcatheter Treatment Market | Abdominal Aortic Aneurysm Market | Adeno Associated Viruses AAV Gene Therapy Market | Anastomosis Device Market | Attention Deficit Hyperactivity Disorder ADHD Market | Bacterial Pneumonia Market | Biopsy Devices Market | Blastomycosis Market | Carcinoid Syndrome Market | Chronic Smell and Flavor Loss Market | Congenital Heart Defect Market | Digestive System Fistula Market | Drug-Resistant Epilepsy Market | Electrophysiology Devices Market | Focal Segmental Glomerulosclerosis Market | Frontotemporal Dementia Pipeline | Geographic Atrophy Market | HDAC Inhibitors Market | Kernicterus Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com